Huapeng M. Lin

Implications of new obesity definitions in the classification and outcomes of patients with MASLD.

Journal: Hepatology (Baltimore, Md.)

Published: April 08, 2026

Risk Assessment in MASLD and MetALD: Current Approaches and Future Directions.

Journal: Clinical and molecular hepatology

Published: March 31, 2026

Bidirectional gut-heart axis interactions in the context of predictive, preventive, and personalised medicine: a time-course analysis of comorbidity and mortality risk in a large population cohort.

Journal: The EPMA journal

Published: January 30, 2026

Characteristics and Outcomes of Patients With Imaging-Defined MASLD and Histological Steatosis Grade S0.

Journal: The American journal of gastroenterology

Published: January 19, 2026

Characteristics and outcomes of patients with imaging-defined MASLD and histological steatosis grade S0.

Journal: The American journal of gastroenterology

Published: January 19, 2026

Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD).

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: January 16, 2026

Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes.

Journal: Gut

Published: November 06, 2025

Progression of Liver Fibrosis and Liver-Related Event Risk in MASLD at High Cardiovascular Risk.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 28, 2025

Progression of Liver Fibrosis and Liver-related Event Risk in Metabolic Dysfunction-associated Steatotic Liver Disease at High Cardiovascular Risk.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 28, 2025

One-Year Changes in Liver Stiffness Measurement, but Not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-Term Liver Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: September 15, 2025

Implications of new obesity definitions in the classification and outcomes of patients with MASLD.

Implications of new obesity definitions in the classification and outcomes of patients with MASLD.

Risk Assessment in MASLD and MetALD: Current Approaches and Future Directions.

Risk Assessment in MASLD and MetALD: Current Approaches and Future Directions.

Bidirectional gut-heart axis interactions in the context of predictive, preventive, and personalised medicine: a time-course analysis of comorbidity and mortality risk in a large population cohort.

Bidirectional gut-heart axis interactions in the context of predictive, preventive, and personalised medicine: a time-course analysis of comorbidity and mortality risk in a large population cohort.

Characteristics and Outcomes of Patients With Imaging-Defined MASLD and Histological Steatosis Grade S0.

Characteristics and Outcomes of Patients With Imaging-Defined MASLD and Histological Steatosis Grade S0.

Characteristics and outcomes of patients with imaging-defined MASLD and histological steatosis grade S0.

Characteristics and outcomes of patients with imaging-defined MASLD and histological steatosis grade S0.

Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD).

Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD).

Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes.

Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes.

Progression of Liver Fibrosis and Liver-Related Event Risk in MASLD at High Cardiovascular Risk.

Progression of Liver Fibrosis and Liver-Related Event Risk in MASLD at High Cardiovascular Risk.

Progression of Liver Fibrosis and Liver-related Event Risk in Metabolic Dysfunction-associated Steatotic Liver Disease at High Cardiovascular Risk.

Progression of Liver Fibrosis and Liver-related Event Risk in Metabolic Dysfunction-associated Steatotic Liver Disease at High Cardiovascular Risk.

One-Year Changes in Liver Stiffness Measurement, but Not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-Term Liver Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

One-Year Changes in Liver Stiffness Measurement, but Not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-Term Liver Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

ONE-YEAR CHANGES IN LSM, BUT NOT IN ALT AND CAP, PREDICT LONG-TERM LIVER OUTCOMES IN PATIENTS WITH MASLD.

ONE-YEAR CHANGES IN LSM, BUT NOT IN ALT AND CAP, PREDICT LONG-TERM LIVER OUTCOMES IN PATIENTS WITH MASLD.

Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD.

Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD.